Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

HCV drug sales drag down Gilead's 1Q18 earnings

May 1, 2018 11:12 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) was off $4.16 to $68.40 in early after-hours trading on Tuesday after reporting 1Q18 earnings that missed analyst estimates for revenue and EPS amid a continued decline in HCV drug sales.

The company posted revenue of $5.1 billion and non-GAAP EPS of $1.48 vs. the Street consensus of $5.4 billion and $1.67, respectively. Sales dropped 22% and EPS fell 34% compared with Gilead's 1Q17 results...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article